• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetic profile of controlled release ketoprofen in elderly patients.老年患者中缓释酮洛芬的药代动力学特征。
Br J Clin Pharmacol. 1985 Dec;20(6):567-73. doi: 10.1111/j.1365-2125.1985.tb05113.x.
2
A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen.酮洛芬新控释剂型重复给药的药代动力学研究。
Int J Clin Pharmacol Ther Toxicol. 1984 Mar;22(3):131-3.
3
Comparative pharmacokinetics of ketoprofen derived from single oral doses of ketoprofen capsules or a novel sustained-release pellet formulation.单次口服酮洛芬胶囊或新型缓释微丸制剂后酮洛芬的比较药代动力学。
Biopharm Drug Dispos. 1984 Jul-Sep;5(3):203-9. doi: 10.1002/bdd.2510050302.
4
Urinary pharmacokinetics of orally administered ketoprofen in man.口服酮洛芬在人体中的尿液药代动力学。
Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):201-4. doi: 10.1007/BF03189642.
5
Pharmacokinetics of a slow-release preparation of ketoprofen lysine in man.酮洛芬赖氨酸缓释制剂在人体中的药代动力学
Arzneimittelforschung. 1983;33(10):1497-500.
6
[Pharmacokinetic profile of a slow-release ketoprofen preparation].[缓释酮洛芬制剂的药代动力学特征]
Sem Hop. 1983 Dec 12;59(46):3187-90.
7
Circadian changes in the pharmacokinetics of oral ketoprofen.口服酮洛芬药代动力学的昼夜变化
Clin Pharmacokinet. 1987 May;12(5):367-78. doi: 10.2165/00003088-198712050-00003.
8
Pharmacokinetics of ketoprofen in patients with chronic renal failure.酮洛芬在慢性肾衰竭患者中的药代动力学。
Scand J Rheumatol. 1981;10(3):189-92. doi: 10.3109/03009748109095297.
9
A comparison of plasma and synovial fluid profiles of standard and controlled-release formulations of ketoprofen in patients with rheumatoid arthritis.类风湿性关节炎患者中酮洛芬标准制剂与控释制剂的血浆及滑液情况比较。
Curr Med Res Opin. 1986;10(2):73-81. doi: 10.1185/03007998609110422.
10
Pharmacokinetics of ketoprofen in the elderly.酮洛芬在老年人中的药代动力学。
Br J Clin Pharmacol. 1983 Jul;16(1):65-70. doi: 10.1111/j.1365-2125.1983.tb02145.x.

引用本文的文献

1
The disposition of ketoprofen enantiomers in man.酮洛芬对映体在人体内的处置。
Br J Clin Pharmacol. 1988 Dec;26(6):765-70. doi: 10.1111/j.1365-2125.1988.tb05317.x.
2
Clinical pharmacokinetic considerations in the elderly. An update.老年人的临床药代动力学考量。最新进展。
Clin Pharmacokinet. 1989 Oct;17(4):236-63. doi: 10.2165/00003088-198917040-00003.
3
Clinical pharmacokinetics of ketoprofen and its enantiomers.酮洛芬及其对映体的临床药代动力学。
Clin Pharmacokinet. 1990 Sep;19(3):197-217. doi: 10.2165/00003088-199019030-00004.

本文引用的文献

1
Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.尿液中酮洛芬、萘普生和丙磺舒原形药物的排泄量可忽略不计。
J Pharm Sci. 1980 Nov;69(11):1254-7. doi: 10.1002/jps.2600691105.
2
Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration.酮洛芬单次口服、肌内注射和直肠给药后以及重复口服给药后的药代动力学。
Eur J Clin Pharmacol. 1980 Nov;18(5):407-14. doi: 10.1007/BF00636794.
3
Pharmacokinetics of ketoprofen in patients with chronic renal failure.酮洛芬在慢性肾衰竭患者中的药代动力学。
Scand J Rheumatol. 1981;10(3):189-92. doi: 10.3109/03009748109095297.
4
Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay.基于一种改进的灵敏且特异的检测方法的酮洛芬药代动力学和生物利用度
Eur J Clin Pharmacol. 1981;20(2):127-33. doi: 10.1007/BF00607149.
5
Single-dose pharmacokinetic study of 900 mg fenbufen in the elderly.
Eur J Rheumatol Inflamm. 1982;5(3):304-7.
6
The pharmacokinetics of benoxaprofen in elderly subjects.老年人中苯恶洛芬的药代动力学。
Eur J Rheumatol Inflamm. 1982;5(2):69-75.
7
Pharmacokinetics of ketoprofen in the elderly.酮洛芬在老年人中的药代动力学。
Br J Clin Pharmacol. 1983 Jul;16(1):65-70. doi: 10.1111/j.1365-2125.1983.tb02145.x.
8
Reduced elimination of ketoprofen in the elderly is not necessarily due to impaired glucuronidation.老年人酮洛芬消除率降低不一定是由于葡萄糖醛酸化受损。
Br J Clin Pharmacol. 1984 Jun;17(6):783-4. doi: 10.1111/j.1365-2125.1984.tb02421.x.
9
A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen.酮洛芬新控释剂型重复给药的药代动力学研究。
Int J Clin Pharmacol Ther Toxicol. 1984 Mar;22(3):131-3.
10
Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients.吡罗昔康在青年、中年和老年患者中的药代动力学观察。
Br J Clin Pharmacol. 1983 Oct;16(4):433-7. doi: 10.1111/j.1365-2125.1983.tb02191.x.

老年患者中缓释酮洛芬的药代动力学特征。

Pharmacokinetic profile of controlled release ketoprofen in elderly patients.

作者信息

Dennis M J, French P C, Crome P, Babiker M, Shillingford J, Hopkins R

出版信息

Br J Clin Pharmacol. 1985 Dec;20(6):567-73. doi: 10.1111/j.1365-2125.1985.tb05113.x.

DOI:10.1111/j.1365-2125.1985.tb05113.x
PMID:4091989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1400814/
Abstract

The pharmacokinetics of ketoprofen following the administration of the first and final dose of a controlled release formulation (200 mg ketoprofen) once daily for 10 days to nine elderly patients have been studied. Plasma ketoprofen concentrations were measured by h.p.l.c. The data were compared to previously reported studies in young male volunteers. Mean +/- s.d. peak plasma concentrations (5.6 +/- 1.75 micrograms ml-1 and 6.3 +/- 2.7 micrograms ml-1 on day 1 and day 10, respectively) were higher than those reported in young volunteers given similar treatment, but similar to those reported in young volunteers following 50 mg four times daily of conventionally formulated ketoprofen, and markedly lower than reported following a single 100 mg dose of ketoprofen. The half-life for drug release (mean +/- s.d.) from the controlled release formulation (8.5 +/- 7.4 h) and accumulation upon repeated dosing (28%) were essentially the same as reported for young volunteers. The area under the plasma concentration-time curve was about 65% greater than reported in young volunteers following administration of controlled release ketoprofen. This increase in exposure to ketoprofen is probably partly due to the lower volume of distribution in the elderly and partly due to a reduced renal excretion of the glucuronide metabolite of ketoprofen. It was concluded that controlled release ketoprofen may be administered in standard doses (200 mg once daily) to elderly patients whose elimination processes are not severely impaired (i.e. severe renal failure or hepatic disease).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

研究了9名老年患者每日1次服用控释制剂(200毫克酮洛芬),连续10天,首剂和末剂给药后酮洛芬的药代动力学。采用高效液相色谱法测定血浆酮洛芬浓度。将数据与之前在年轻男性志愿者中进行的研究进行比较。平均±标准差的血浆峰浓度(第1天和第10天分别为5.6±1.75微克/毫升和6.3±2.7微克/毫升)高于接受类似治疗的年轻志愿者报告的浓度,但与年轻志愿者每日4次服用50毫克常规制剂酮洛芬后报告的浓度相似,且明显低于单次服用100毫克酮洛芬后报告的浓度。控释制剂的药物释放半衰期(平均±标准差)(8.5±7.4小时)和重复给药后的蓄积率(28%)与年轻志愿者报告的基本相同。血浆浓度-时间曲线下面积比服用控释酮洛芬后的年轻志愿者报告的约大65%。酮洛芬暴露量的增加可能部分归因于老年人分布容积较低,部分归因于酮洛芬葡萄糖醛酸代谢物肾排泄减少。得出结论,对于消除过程未严重受损(即严重肾衰竭或肝病)的老年患者,可按标准剂量(每日1次,200毫克)给予控释酮洛芬。(摘要截短于250字)